医药营销
- (2019-12-13)
- (2019-12-13)
- (2019-12-13)
- (2019-12-12)
- (2019-12-12)
阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人,HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月
(2019-12-12)- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-12)
- (2019-12-11)
- (2019-12-11)
- (2019-12-11)
- (2019-12-11)
- (2019-12-11)
- (2019-12-11)
- (2019-12-11)
- (2019-12-11)
- (2019-12-11)
- (2019-12-11)
- (2019-12-10)
- (2019-12-10)
- (2019-12-10)
- (2019-12-10)
- (2019-12-10)
- (2019-12-10)
- (2019-12-10)
- (2019-12-10)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-09)
- (2019-12-08)
- (2019-12-08)
- (2019-12-08)
- (2019-12-08)
- (2019-12-08)
- (2019-12-08)
- (2019-12-08)